Next Article in Journal
Atoms in Generalized Orbital Configurations: Towards Atom-Dedicated Density Functionals
Next Article in Special Issue
Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy
Previous Article in Journal
Puf6 and Loc1 Are the Dedicated Chaperones of Ribosomal Protein Rpl43 in Saccharomyces cerevisiae
Previous Article in Special Issue
Beyond the Cell Surface: Targeting Intracellular Negative Regulators to Enhance T cell Anti-Tumor Activity
Open AccessReview

CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges

by , and *,†
Department of Dermatology, Universtitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Hartmannstraße 14, 91052 Erlangen, Germany
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Current address: Klinik und Poliklinik für Innere Medizin III, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.
Int. J. Mol. Sci. 2019, 20(23), 5942; https://doi.org/10.3390/ijms20235942
Received: 24 October 2019 / Revised: 21 November 2019 / Accepted: 23 November 2019 / Published: 26 November 2019
(This article belongs to the Special Issue CAR-T Cell Therapy)
Targeting cancer cells using chimeric-antigen-receptor (CAR-)T cells has propelled adoptive T-cell therapy (ATT) to the next level. A plentitude of durable complete responses using CD19-specific CAR-T cells in patients suffering from various lymphoid malignancies resulted in the approval by the food and drug administration (FDA) of CD19-directed CAR-T cells for the treatment of acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). A substantial portion of this success in hematological malignancies can be traced back to the beneficial properties of the target antigen CD19, which combines a universal presence on target cells with no detectable expression on indispensable host cells. Hence, to replicate response rates achieved in ALL and DLBCL in the realm of solid tumors, where ideal target antigens are scant and CAR-T cells are still lagging behind expectations, the quest for appropriate target antigens represents a crucial task to expedite the next steps in the evolution of CAR-T-cell therapy. In this review, we want to highlight the potential of chondroitin sulfate proteoglycan 4 (CSPG4) as a CAR-target antigen for a variety of different cancer entities. In particular, we discuss merits and challenges associated with CSPG4-CAR-T cells for the ATT of melanoma, leukemia, glioblastoma, and triple-negative breast cancer. View Full-Text
Keywords: CSPG4; target antigen; CAR-T cell; melanoma; leukemia; glioblastoma; triple-negative breast cancer CSPG4; target antigen; CAR-T cell; melanoma; leukemia; glioblastoma; triple-negative breast cancer
Show Figures

Figure 1

MDPI and ACS Style

Harrer, D.C.; Dörrie, J.; Schaft, N. CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges. Int. J. Mol. Sci. 2019, 20, 5942. https://doi.org/10.3390/ijms20235942

AMA Style

Harrer DC, Dörrie J, Schaft N. CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges. International Journal of Molecular Sciences. 2019; 20(23):5942. https://doi.org/10.3390/ijms20235942

Chicago/Turabian Style

Harrer, Dennis C.; Dörrie, Jan; Schaft, Niels. 2019. "CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges" Int. J. Mol. Sci. 20, no. 23: 5942. https://doi.org/10.3390/ijms20235942

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop